Drug Profile
R 190
Alternative Names: R-190Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Radikal Therapeutics
- Class Anti-ischaemics; Small molecules; Urologics
- Mechanism of Action Nitric oxide donors; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacteraemia; Bronchopulmonary dysplasia; Hypertension; Kidney disorders; Pulmonary arterial hypertension; Renal failure; Reperfusion injury
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Renal-failure in USA (IV)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Reperfusion-injury in USA (IV)
- 03 Dec 2019 Preclinical development for Reperfusion injury is ongoing in USA (Radikal Therapeutics pipeline, November 2019)